Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with

AP Biosciences, a clinical─stage biopharmaceutical company dedicated to transforming cancer therapy through development of innovative bispecific antibodies, announced that it has dosed the first patient in its phase 1 study

Nature Reviews Cancer, Published online: 24 April 2025; doi:10.1038/s41568-025-00821-y

AbstractBackgroundPrecise patient positioning is crucial for successful radiotherapy, ensuring accurate delivery of radiation to tumors while minimizing exposure to healthy tissues. Positional errors can significantly impact treatment efficacy and increase side effects. This study evaluates the effectiveness of daily cone beam computed tomography (CBCT) imaging in the Halcyon system for detecting and correcting patient misalignments across various cancer types and treatment sites.MethodsA retrospective analysis was conducted on 411 patients treated with the Varian Halcyon linear accelerator from August 2022 to August 2024. Patients were grouped based on tumor location: Head and Neck (118 patients), Chest (188 patients), and Pelvis (105 patients). Daily pre-treatment CBCT scans were performed to verify positioning, with shifts in the x, y, and z axes quantified and adjusted using automated couch corrections.ResultsThe study revealed average positional shifts along the x-axis of ~0.112 cm, while both the Chest and Pelvic groups recorded 0.194 cm. The y-axis deviations were 0.135 cm for Head and Neck, 0.206 cm for Chest, and 0.195 cm for the Pelvis. On the z-axis, a mean deviation of 0.07 cm was found for the Head and Neck group, while 0.11 cm for the Chest group, and 0.085 cm for the Pelvic group. The Head and Neck group exhibited the smallest standard deviations across all axes, indicating greater positional consistency. Normalized density distributions showed distinct emergent patterns, the Head and Neck group showing tighter distributions compared to the broader distributions observed in the Chest and Pelvic groups.ConclusionsDaily CBCT imaging in the Halcyon system significantly enhances patient positioning accuracy in radiotherapy. The findings demonstrate that this approach minimizes positional shifts, particularly in the Head and Neck region, essential for optimizing treatment outcomes and reducing the risk of adverse effects. Future studies should further explore the integration of advanced imaging techniques to improve precision in patient positioning.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Nature Reviews Gastroenterology & Hepatology, Published online: 14 April 2025; doi:10.1038/s41575-025-01062-y

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as skin, lung, or bone and soft tissue cancer (sarcomas), they have not yet proven themselves as a treatment method. Tumor shrinkage was achieved only in rare cases, but the side effects were all the more severe. An international research group led by scientists has now succeeded in a phase 1 clinical trial in testing a novel cell therapy approach that also shows promise for solid tumors.

Non-small cell lung cancer (NSCLC) constitutes approximately 85?% of all lung cancer cases and the leading cause of cancer-related mortality worldwide, including Europe and Spain [1,2]. Traditional treatment approaches for NSCLC patients, such as chemotherapy and radiation, have shown limited efficacy advanced-stage NSCLC [3,4]. However, advances in molecular biology have paved the way for the development of targeted therapies that exploit specific molecular alterations in tumor cells. In this way, biomarker testing has revolutionized the treatment for NSCLC, expanding the therapeutic opportunities of these patients as well as improving their quality of life [5–9].

Non-small cell lung cancer (NSCLC) constitutes approximately 85?% of all lung cancer cases and the leading cause of cancer-related mortality worldwide, including Europe and Spain [1,2]. Traditional treatment approaches for NSCLC patients, such as chemotherapy and radiation, have shown limited efficacy advanced-stage NSCLC [3,4]. However, advances in molecular biology have paved the way for the development of targeted therapies that exploit specific molecular alterations in tumor cells. In this way, biomarker testing has revolutionized the treatment for NSCLC, expanding the therapeutic opportunities of these patients as well as improving their quality of life [5–9].

Source: Experimental Cell Research

Patients could soon benefit from world─leading technology to diagnose bowel cancer earlier, faster and cheaper, reducing the need for invasive colonoscopies and biopsies, and potentially saving valuable time and

Researchers trained and validated a deep learning model that can detect subtle changes across post-treatment brain scans and forecast glioma recurrence with up to 89 percent accuracy.

ViroCell Biologics has manufactured a GMP-grade lentiviral vector for a University College London (UCL) clinical trial aimed at tackling relapse in pa...

An international team has identified a potential microbial culprit behind the alarming rise in early-onset colorectal cancer: a bacterial toxin called colibactin. Scientists report that exposure to colibactin in early childhood imprints a distinct genetic signature on the DNA of colon cells -- one that may increase the risk of developing colorectal cancer before the age of 50.

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as skin, lung, or bone and soft tissue cancer (sarcomas), they have not yet proven themselves as a treatment method. Tumor shrinkage was achieved only in rare cases, but the side effects were all the more severe. An international research group led by scientists has now succeeded in a phase 1 clinical trial in testing a novel cell therapy approach that also shows promise for solid tumors.

Journal of Clinical Oncology, Ahead of Print.

Oncogene, Published online: 12 April 2025; doi:10.1038/s41388-025-03375-3